Safety and immunogenicity of influenza A H5 subunit vaccines: Effect of vaccine schedule and antigenic variant

Journal of Infectious Diseases

Volumn 203, Issue 5, 2011, Pages 666-673

  Belshe, Robert B ^a   Frey, Sharon E ^a   Graham, Irene ^a   Mulligan, Mark J ^b   Edupuganti, Srilatha ^b   Jackson, Lisa A ^c   Wald, Anna ^d   Poland, Gregory ^e   Jacobson, Robert ^e   Keyserling, Harry L ^b   Spearman, Paul ^b   Hill, Heather ^f   Wolff, Mark ^f  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c GROUP HEALTH RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e MAYO CLINIC   (United States)

^f EMMES CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMAGGLUTININ; INFLUENZA A H5 SUBUNIT VACCINE; INFLUENZA VACCINE; UNCLASSIFIED DRUG;

ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN ANTIBODY REACTION; ARTICLE; CLADISTICS; DRUG EFFECT; DRUG SAFETY; FEMALE; HUMAN; HUMAN EXPERIMENT; IMMUNE RESPONSE; IMMUNOGENICITY; MALE; NORMAL HUMAN; PRIORITY JOURNAL; VACCINATION;

ADOLESCENT; ADULT; ANTIBODIES, VIRAL; ANTIGENIC VARIATION; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMMUNIZATION, SECONDARY; INFLUENZA A VIRUS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; VACCINES, SUBUNIT; YOUNG ADULT;

EID: 79751471067     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jiq093     Document Type: Article

References (12)

1. Tran TH, Nguyen TL, Nguyen TD, et al. Avian influenza A (H5N1) in 10 patients in Vietnam. N Engl J Med 2004; 350:1179-88.
2. Ungchusak K, Auewarakul P, Dowell SF, et al. Probable person-to-person transmission of avian influenza A (H5N1). N Engl J Med 2005; 352:333-40.
3. Nicholson KG, Colegate AE, Podda A, et al. Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/ 97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet 2001; 357:1937-43. (Pubitemid 32568336)
4. Treanor JJ, Wilkinson BE, Masseoud F, et al. Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. Vaccine 2001; 19:1732-7. (Pubitemid 32175735)
5. Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 2006; 54:1343-51.
6. Stephenson I, Nicholson KG, Colegate AE, et al. Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population. Vaccine 2003; 21:1687-93. (Pubitemid 36287599)
7. Stephenson I, Bugarini R, Nicholson KG, et al. Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with non-adjuvanted andMF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy. J Infect Dis 2005; 191:1210-5.
8. Goji NA, Nolan C, Hill H, et al. Immune responses of healthy subjects to a single dose of intramuscular inactivated influenza A/Vietnam/ 1203/2004 (H5N1) vaccine after priming with an antigenic variant. J Infect Dis 2008; 198:635-41.
9. Noah DL, Hill H, Hines D, White EL, Wolff MC. Qualification of the hemagglutination inhibition assay in support of pandemic influenza vaccine licensure. Clin Vaccine Immunol 2009; 16:558-66.
10. Rowe T, Abernathy RA, Hu-Primmer J, et al. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol 1999; 37:937-43. (Pubitemid 29140593)
11. Sanofi Pasteur. Influenza virus vaccine, H5N1. Full prescribing information http://www.fda.gov/downloads/BiologicsBloodVaccines/ Vaccines/ApprovedProducts/UCM112836.pdf. Accessed 23 June 2010.
12. National Center for Immunization, Respiratory Diseases, CDC. Use of influenza A(H1N1) 2009 monovalent vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR 2009; 58:1-8.